Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings

Set Alert for Sales & Earnings

MorphoSys Pins Hopes On Pelabresib For Near-Term Value After Tumultuous 2022

The German biotech has highlighted its myelofibrosis drug candidate, pelabresib, as a key value driver going forward after a year of hard knocks and lackluster Monjuvi sales that forced the firm to downsize its workforce and cease preclinical operations.

Cancer Sales & Earnings

Ferring Reflects On Fruitful 2022 As Filing Costs Hit Profits

While reproductive medicine and maternal health remains the mainstay for the Swiss group, Ferring president Per Falk says the approvals of the microbiome treatment Rebyota and bladder cancer gene therapy Adstiladrin represent "important avenues for exploration and growth."

Sales & Earnings Business Strategies

Zealand Eyes Opportunities In Burgeoning Obesity Market

Given the renewed interest in the commercial potential of obesity therapies, Zealand is heralding the potential of its treatments for the overweight.

Metabolic Disorders Business Strategies

Merck KGaA Expects Modest Growth Ahead Of Launches Next Year

The German firm is eyeing licensing opportunities in 2023 to fill up its mid-stage pipeline.

Sales & Earnings Business Strategies

Theravance Dumps JAK Inhibitor Program, Focuses On Neurogenic Orthostatic Hypotension

Ampreloxetine failed in a Phase III trial in 2021, but the company will start a registrational trial by the end of Q1 for the drug in the multiple system atrophy population, where it has shown efficacy.

Sales & Earnings Cardiovascular

No Slowdown From Bayer On Business Development Front

“We're looking at opportunities almost on a weekly basis,” Bayer’s pharma chief Stefan Oelrich told Scrip as the German major posted a solid set of financials for the fourth quarter.

Sales & Earnings Business Strategies

Calliditas Confident Of Keeping Ahead Of Travere In IgAN

The Swedish group’s Tarpeyo is reaping the benefits of an expanded US sales force and the company is confident of a big revenue rise in 2023, regardless of new competition in the IgAN field from Travere’s Filspari.

Sales & Earnings Business Strategies

With COVID Crash In Sight, Moderna’s Post-Pandemic Future Starts To Take Shape

The company reported a fourth quarter decline in SARS-CoV-2 vaccine sales and guided for sales of $5bn in 2023. It is looking ahead to filing for approval of its RSV vaccine.

Sales & Earnings Coronavirus COVID-19

UCB Bullish On Bimzelx Despite Sluggish Start

While sales for the dual interleukin-17A and IL-17F inhibitor only reached €35m last year, UCB immunology chief Emmanuel Caeymaex is confident that figure will leap over the €200m barrier in 2023, if US approval for Bimzelx for psoriasis comes in the next quarter. 

Sales & Earnings Business Strategies

Biocon Biologics CEO On Interchangeability Dynamics For Humira Biosimilar

Biocon Biologics’ CEO indicates that interchangeability may not be pivotal to commercial success in the US for biosimilar adalimumab and that the firm’s Humira rival “checks the key boxes.”

Commercial Biosimilars

Seagen To Surge Ahead As ADCs Become Frontline Cancer Therapies

Putting its CEO crisis and takeover rumors behind it, Seagen has big plans to expand its leading position in antibody-drug conjugates in 2023.

Sales & Earnings Commercial

Pharma Execs: China Slowly Returning To Growth But Uncertainty Remains

Just how dynamic is the China market for multinationals? AstraZeneca is seeing growth returning while Pfizer is finding it challenging to estimate Paxlovid demand, Sanofi is encouraged by volume gains and GSK is predicting a "sizeable" rebound. Top executives from Novartis and Roche also shed light on other challenges facing global pharma firms in the world's second-largest pharma market as they reported annual results.

China Commercial
UsernamePublicRestriction

Register